Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Investor Presentation (October 2013)
34 slides from Sorrento Therapeutics's investor presentation, Oct 4, 2013
Slide 1: Sorrento Therapeutics: Next-Generation Cancer Therapeutics
Exhibit 99.1 Exhibit Therapeutics Sorrento Cancer Next-Generation October 99.1 2013 Therapeutics
Slide 2: Safe Harbor Statement
Safe This regarding or as Cynviloq™ presentation. Assumptions information. 2Exchange all well Harbor presentation ofasthe our risks Commission, pending will Statement The and business, inherent be contains other Company amatters review OTC information technologies including in “forward-looking fundi
Slide 3: Management Team and Board of Directors
Management Inventor Founder George CCO $430M divestitures Board David Celgene Ernst-Günther Hoechst Cam Nerveda, Kim The Henry M. Ambit Jaisim PDL Vuong Richard 3Sorrento Scott Scripps D. (former Gallagher ofWebb, of Ji, Biosciences Shah Trieu, sale Uy Janda, IgDraSol Vincent (former and of (CEO) (C
Slide 4: Investment Highlights
Investment Late Addresses Abbreviated Bioequivalence Product Therapeutic First Targeted Antibody Small Toxin Paclitaxel 4Cynviloq™ Stage antibody for Molecule launch Drug Antibody market as for multi-billion Oncology Highlights G-MAB® antibody specific regulatory Antibody drug Delivery in registrati
Slide 5: Sorrento's Next-generation Cancer Therapeutics
Sorrento’s Next-generation Cynviloq™ Bioequivalence Efficacy US High-diversity G-MAB® Lead FTO AfDC: Effective ADC: G-MAB 5Programs and and mAb Antibody Antibody EUtargets demonstrated no against include Next-Generation programs rights stacking human (BE) approved toxin Drug Abraxane® formulated het
Slide 6: Pipeline
PHASE Pipeline Metastatic }505(b)(2) Non-Small Pancreatic Bladder Ovarian INDICATION AfDC ADC G-MAB® Cynviloq™ Oncology 1H 6*Multiple 2014Cancer 2Abraxane® Strategic 1H PHASE >Cancer Breast Bioequivalence Cell VEGFR2, PD-L1, 2015 >(sNDA) Lung TARGET Cancer (BE* Partnership 3 VEGFR2, PD-1, NDA orphan
Slide 7: Oncology Phase 3 Cynviloq Franchise
Oncology Phase 7Cynviloq™ 3 Franchise
Slide 8: Cynviloq: Maximum Tolerated Dose Formulation
Cynviloq Maximum Formulation Generation Peak Taxol® 1st Cremophor 175 ~ 2nd 3rd *Analyst 8indications $1.6B Cynviloq™ Abraxane® mg/m2 Product paclitaxel (WW projection isTolerated EL the Sales inexcipient: 3rd paclitaxel nab-paclitaxel 2000) Generation ;Dose in Metastatic Polyoxyethylated polymeric
Slide 9: Cynviloq Value Proposition: Exclusive Rights, Large Market
Cynviloq 1. 2. 3. Lung 94. Exclusive Cynviloq FDA Large Cancer) concurred market is aefficacy USHigh opportunity and a.Value Available EU demonstrated Rights Proposition a. data Abraxis in support Phase (Abraxane®) pursuing 2 and Phase 505(b)(2) sold3 to studies Celgene regulatory for >pathway $3B b
Slide 10: Bioequivalence: Direct and Efficient Pathway
Bioequivalence 12 Direct Cycle Abraxane® Dose: Cmax 10 months 1260 2(90% trialmg/m2 of cost (50 CI) duration ~$5M = registration patients) Efficient Infusion (including Abraxane® time: Pathway study30 patient in min to breast Cynviloq™ Market Duration: recruitment) cancer(50 patients 3 weeks patient
Slide 11: Cynviloq US Market Opportunity: Number of Patients Treated
Cynviloq -3#~70,000 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 100,000 NSCLC Other ~55,000 15,903 Note: Sources: http://www.who.int/whosis/whosis/. represent 11 0,766 of Patients In regimens 14,479 PCMBC patients Pancreatic US treatable Market patients information, Treated Pancre
Slide 12: Cynviloq Advantages
Cynviloq™ Maximum Advantage Cynviloq Taxol® Potential 175 260 >300 Rapid Convenience Convenient No Chemical Reduced Cremophor-free q3w* Dosing q3w *Exploits donor-derived viral requirement microbial &&reconstitution: weekly = weekly** /PK side for Advantages polymer prion MBC; Tolerated storage Abra
Slide 13: Potential For Cynviloq to Expand Label
Potential For Cynviloq Best 21% Progression -2.7 Overall 6.5 2.3 High Summary: Demonstrated *Phase /advanced #13 ** 0%*** 1.5 M M** Example: Supportive unmet AUA-3-ready M*** Response Survival Invest /to Phase 4.3 Expand Free need—no San M*** 2nd clinical for New 2Care Survival development (Korea)*
Slide 14: Next Steps: Bioequivalence Trial and NDA
Next 1. 2. 3. 4. 5. Bioequivalence NDA FDA 2014 LAUNCH 14 2016 Approval: Bioequivalence NDA Product sNDA Approval Steps 2014/ Filing filing: planning launch for 2015 2015 Cynviloq 2014 Trial 2016 for (BE) /for 2016 / MBC 2015 label trial: a. expansion and Metastatic 2014 NSCLC: into Breast 2016 Blad
Slide 15: Therapeutic Antibody Engine: Extensive G-MAB Pipeline
Therapeutic Extensive G-MAB® 15 Pipeline Antibody Engine
Slide 16: G-MAB Proprietary Antibody Library Technology
-•G-MAB®: RNA Proprietary No Difficult Small Most High Size 16 AIP-4 AIP-3 AIP-2 AIP-1of Value Library Difficult Peptides Target technology Freedom-To-Operate amplification stacking Targets: Oncologyofused Antigen Targets:Therapeutic royalties Very • Fully High for Targets:2.1 high xAntibodies human
Slide 17: Anti-PD-L1 Immune Modulation
Anti-PD-L1 Immune ITumor 3000 6000 9000 12000 15000 T 200 400 600 01800 10 20 30 40 50 Competitor Day 25 *Sorrento FN-? L-2 5umor 17 ** ***Cell (pg/mL) (pg/mL) Activation Mouse Growth mAbs Modulation* mAb xenograft p<0.05, mAb mAbs Model** @ meanInhibition model(%) 0.05 Exhibit tumormg/mL using (%)
Slide 18: Anti-PD-1 Immune Modulation
Anti-PD-1 IIL-2 200 400 600 800 1000 T 5000 10000 15000 5normalized 10 15 20 25 18 0CNF-? cellConcentration Activation Concentration Sorrento ompetitor mAbmAbs to untreated mAbs (% Exhibit (pg/mL) CD25+ (pg/mL) control Potent ) Immune Modulation
Slide 19: Potent Autoimmune Disease mAb
3.5 Potent Disease mAb (EC50 Sorrento Competitor 3Untreated 219 2.5 10.5 1.5 ** 14Cell Antibody –nM) Score** 0.17 After 15 Binding Sorrento 21 17 18against 03 Experimental *Days Sorrento 16 Disease mAb mAb 19 Difficult Induction 20against 21 22 23 Auto-immune C-CGPCR Target* 24Chemokine 25 26 27 28R
Slide 20: Targeted Drug ADC/AfDC Formulation Platform
Targeted Drug ADC/AfDC 20 G-MAB®+Payload Formulation Platform
Slide 21: Antibody Drug Conjugates: Components and Mechanism
Antibody 32Key 1. 2. 3. Drug 21 Components: Potent Linker Drugconjugation ADC released binds is 54 Target-specific Cytotoxic ApoptosisConjugates cytotoxic and in 1agent ADC to receptor (cell CANCER isin internalized (ADC) death) internalizing prodrugs plasma released chemistries CELL antibody
Slide 22: Anti-VEGFR2 and Anti-c-Met ADCs Demonstrate Enhanced Activity
Anti-VEGFR2 Anti-c-Met 0(% 50 0.01 *10.001 **.0001 100 IgG of80 Leading0.1 Relative Sorrento 22 non Viability pCompetitor Cell ADCs treated value<0.0001 ADC** Viability Concentration Human 60 Human ADC 40 ADC* Demonstrate cells) 20(mAb A549 Vascular 0NSCLC 0.0001 (nM) mAb Enhanced + Toxin) Endotheli
Slide 23: Anti-CXCR3 and Anti-CXCR5 ADCs Demonstrate Enhanced Activity
Anti-CXCR3 Anti-CXCR5 Relative (% 100 = Sorrento *IgG 23 **pCells of 0. 50 Concentration non 0015**value 0Cells Cell ADC anti-GPCR naked 0.001 treated Viability ADC* ADC** expressing (mAb 0.01 mAb expressingcells) =human (nM) 0.1 ADCs pToxin + 0. Toxin) 150 100035**value human IgG Demonstrate Contro
Slide 24: Antibody Drug Conjugates (AfDC) Key Features
Antibody Key 1. 2. 3. 214. 3 Approved NoFeatures: Multiple Effective Drug TUMOR 24 internalization formulated mAbs against AfDCchemotherapeutics inTUMOR plasma / agent inbinds Cytotoxic released drug heterogeneous required Drug to combinations is Conjugates cancer with releasedtumors known antigens
Slide 25: G-MAB and ADC/AfDC Pipeline
G-MAB®, G-MAB® PD-1 VEGFR2-ADC EGFR c-Met PD-L1 CGRP CCR2 ONCOLOGY (GPCR) INFLAMMATION CXCR5 MRSA INFECTIOUS Multiple DISEASE 25 (STI-A110X) (STI-A150X) (STI-B020X) (STI-A020X) (STI-B150X) (STI-A100X) (STI-B010X) (STI-C020X) (STI-B030X) CXCR3 Strategic Antibody ADC / CCR2 (STI-A0168) and (STI-A120X)
Slide 26: Positioned to Become Oncology Leader
Positioned toPhase ADC/AfDC G-MAB® Cynviloq™ 26 Become 3 Extensive OncologyPipeline Leader G-MAB + Payload
Slide 27: Small Company Valuations vs. Peers
Small~$1.5B Company Sorrento: (Ph3/Registration Puma: MBC Clovis: NSCLC, MorphoSys: ~$2.0B ~$1.4B Pre-revenue ~$450M Seattle ImmunoGen: *ADC 27 ~$5.4B (Phase Molecule PBYI Genetics: CLVS based MBC SRNE Small Library MOR.DE 3) Product Royalty IMGN on Antibody (Phase ~$1.6B Oncology Molecule ADC SGEN
Slide 28: Investment Highlights
Investment Late ADC/AfDC G-MAB® •Cynviloq™ Addresses Stageantibody Product •Therapeutic Antibody First Oncology Highlights Abbreviated multi-billion Bioequivalence launch antibody market Drug regulatory with dollar registration in drug 1H 2016 engine >$50B in candidateExclusive pathwaypaclitaxel tri
Slide 29: Financials and Capitalization
Financials Cash Total Common Options Warrants Current IgDraSol Assignment Pro Weighted 29 Forma and Debt Capitalization Granted Outstanding Milestone Cash Stock average & $Capitalization Issuances: Agreement 5.0M Capitalization Equivalents Outstanding &exercise Outstanding 1,306,272 (2) 17,034,784 8
Slide 30: Contact: Henry Ji, President and CEO
Sorrento Henry Next-Generation Contact: PresidentTherapeutics and CEO JiCancer hji@sorrentotherapeutics.com Therapeutics (858) 668-6923
Slide 31: Cynviloq Clinical Stage Trial Results
Cynviloq Clinical Stage MBC, PC, Phase Post Total (Safety) -US p45 n=105 Cynviloq™Taxol® South 31 No =40 approval 0.03 OC, Market obvious 946 Trial 35 1Korea* 2 3NSCLC, n=104 study MTD 259 MBC Exposures pBC 30 : =Interim Patients 25 MBC, 0.001 for ethnic n=209 in United 80 105 20Abraxane® MBC 15 pRe
Slide 32: Simulated Comparison of Cmax
Simulated Comparison Cmax (ng/mL) CynviloqTM (Simulated 99.6% Abraxane® (Actual Note: Per *Cynviloq™ 32 FDA Internal Ratio 109.2% PK)* Gardner Cmax(T)/Cmax(R) requirement, PK PK) 19556 vs. (T) data AUCinf of19486 calculations Parameters mean Abraxane® and on et20324 al, file Abraxane® 22198 Ratio no
Slide 33: Why Antibody Drug Conjugates
Why Clinical Most Excellent Limited Predictable Good Effector Recruitment Tunable Engineering Targeted Antibody Hinge Feb sFc 33 region region Antibody successful serum region off-target track drug functions delivery target Drug Feb PK/PD of half characteristics record Fc Therapeutics PK patient’s C
Slide 34: Top Global Therapeutic Antibodies
TopGlobal 2012 mAb US Humira Enbrel Rituxan Remicade Herceptin Avastin Lucentis Erbitux Tysabri Xolair 34 10 Target Sales (Omalizumab) (Etanercept) Selling (Natalizumab) (Cetuximab) (Bevacizumab) (Adalimumab) (Rituximab) (Ranibizumab) (Trastuzumab) (Infliximab) Companies Therapeutic TNF EGFR CD20 Ig
Sorrento Therapeutics — Investor Presentation (October 2013) on 6ix